Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Cross-reactivity00:42

Cross-reactivity

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.

Journal of experimental & clinical cancer research : CR·2026
Same author

Antimetastatic activity of B7-H3-targeted CAR T-cell therapy in triple-negative breast cancer.

Cancer letters·2026
Same author

HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model.

Translational oncology·2025
Same author

Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results.

Nature medicine·2025
Same author

B7-H3 and CSPG4-targeted CAR T cells as potent effectors in anaplastic thyroid cancer.

Journal of experimental & clinical cancer research : CR·2025
Same author

IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer.

Molecular cancer·2025

Related Experiment Video

Updated: May 29, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Hidden immunotherapy targets challenge dogma.

Soldano Ferrone1

  • 1University of Pittsburgh Cancer Institute, PA 15213, USA. ferrones@upmc.edu

Science Translational Medicine
|September 9, 2011
PubMed
Summary

Intracellular tumor antigen-specific monoclonal antibodies show promise in inhibiting tumor growth and metastasis. This immunotherapy approach may prolong survival in mice with tumors, warranting further investigation into its mechanisms.

Area of Science:

  • Oncology
  • Immunotherapy
  • Translational Medicine

Background:

  • Monoclonal antibodies (mAbs) are a cornerstone of modern cancer therapy.
  • Targeting extracellular tumor antigens with mAbs is well-established.
  • The potential of targeting intracellular tumor antigens remains largely unexplored.

Purpose of the Study:

  • To discuss the implications of targeting intracellular tumor antigens with monoclonal antibodies (mAbs) in cancer immunotherapy.
  • To explore the potential mechanisms of action for intracellular mAb-based immunotherapy.
  • To evaluate the impact of intracellular mAb immunotherapy on tumor growth, metastasis, and survival.

Main Methods:

  • Review and discussion of findings presented by Guo et al. in Science Translational Medicine.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

  • Analysis of theoretical frameworks for intracellular antibody delivery and function.
  • Examination of preclinical data on tumor-bearing mouse models.

    • Main Results:

    • Intracellular tumor antigen-specific mAbs demonstrated inhibition of tumor growth and metastasis in preclinical models.
    • These novel mAbs were associated with prolonged survival in tumor-bearing mice.
    • The study highlights the potential of intracellular targeting for enhancing mAb immunotherapy efficacy.

    Conclusions:

    • Targeting intracellular tumor antigens represents a novel and promising strategy in mAb immunotherapy.
    • Further research into the mechanisms of action is crucial for clinical translation.
    • Intracellular mAb-based immunotherapy holds potential for improving outcomes in cancer patients.